Abstract
Tumor-homing and pH-responsive polypeptide-drug nanoparticles for targeted cancer therapy are precisely designed by site-specific drug conjugation to a bioactive and well-defined elastin-like polypeptide through an acid-labile linker. In a murine cancer model, these nanoparticles show significantly better anti-tumor efficacy and less systemic toxicity than not only free drugs, but also polypeptide-drug nanoparticles without the tumor-homing function.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acid Sequence
-
Animals
-
Antibiotics, Antineoplastic / administration & dosage*
-
Antibiotics, Antineoplastic / adverse effects
-
Antibiotics, Antineoplastic / pharmacokinetics
-
Antibiotics, Antineoplastic / therapeutic use
-
Cell Line, Tumor
-
Delayed-Action Preparations / adverse effects
-
Delayed-Action Preparations / chemistry*
-
Doxorubicin / administration & dosage*
-
Doxorubicin / adverse effects
-
Doxorubicin / pharmacokinetics
-
Doxorubicin / therapeutic use
-
Drug Delivery Systems
-
Elastin / adverse effects
-
Elastin / chemistry
-
Humans
-
Hydrogen-Ion Concentration
-
Mice
-
Molecular Sequence Data
-
Nanoparticles / adverse effects
-
Nanoparticles / chemistry*
-
Neoplasms / drug therapy
-
Neoplasms / pathology
-
Peptides / adverse effects
-
Peptides / chemistry*
Substances
-
Antibiotics, Antineoplastic
-
Delayed-Action Preparations
-
Peptides
-
Doxorubicin
-
Elastin